More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.03B
EPS
-0.7
P/E ratio
--
Price to sales
3.56
Dividend yield
--
Beta
1.214522
Previous close
$28.83
Today's open
$28.72
Day's range
$28.45 - $29.69
52 week range
$25.92 - $42.81
show more
CEO
Jack A. Khattar
Employees
838
Headquarters
Rockville, MD
Exchange
Nasdaq Global Select
Shares outstanding
207724098
Issue type
Common Stock
Healthcare
Pharmaceuticals
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.
GlobeNewsWire • Nov 10, 2026

This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benzinga • Nov 9, 2026

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.
GlobeNewsWire • Nov 2, 2026

Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals.
MarketBeat • Oct 29, 2026

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

Supernus Announces Third Quarter 2026 Financial Results
ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.
GlobeNewsWire • Oct 29, 2026

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.
Zacks Investment Research • Oct 30, 2026

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 22, 2026

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
GlobeNewsWire • Oct 21, 2026

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.
GlobeNewsWire • Oct 19, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Supernus Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.